Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTURA I
2019-004369-42Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Mean absolute change from baseline in DAS28-ESR at Week 24. Started Mar 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-004369-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004369-42.